EGFR and metastatic colorectal cancer: The American Society of Clinical Oncology (ASCO) published guidelines in 2009 recommending all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) treatment [3].